Managing migraine in pregnancy and breastfeeding.
| Autor: | Parikh SK; Thomas Jefferson University, Philadelphia, PA, United States., Delbono MV; Thomas Jefferson University, Philadelphia, PA, United States., Silberstein SD; Thomas Jefferson University, Philadelphia, PA, United States. Electronic address: stephen.silberstein@jefferson.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Progress in brain research [Prog Brain Res] 2020; Vol. 255, pp. 275-309. Date of Electronic Publication: 2020 Aug 18. |
| DOI: | 10.1016/bs.pbr.2020.07.011 |
| Abstrakt: | The disproportionate prevalence of migraine among women in their reproductive years underscores the clinical significance of migraine during pregnancy. This paper discusses how migraine evolves during pregnancy, secondary headache disorders presenting in pregnancy and puerperium, and acute and preventive options for migraine management during pregnancy and lactation. Migraine is influenced by rising estrogen levels during pregnancy and their sharp decline in puerperium. Migraine, and migraine aura, can present for the first time during pregnancy and puerperium. There is also a higher risk for the development of preeclampsia and cerebrovascular headache during these periods. New or refractory headache, hypertension, and abnormal neurological signs are important "red flags" to consider. This paper reviews the diagnostic utility of neuroimaging studies and the risks of each during pregnancy. Untreated migraine can itself lead to preterm delivery, preeclampsia, and low birth weight infants. Behavioral interventions and lifestyle modifications are the cornerstone for migraine treatment during pregnancy. In addition, one should consider the risks and efficacy of each treatment during pregnancy on an individual basis. The protective nature of breastfeeding for migraine is debated, but there is no evidence to suggest breastfeeding worsens migraine. Acute and preventive migraine treatment options are available for nursing mothers. Neuromodulation and neurostimulation devices are additional options for treatment during pregnancy and lactation, while the safety of using calcitonin gene-related peptide receptor antagonists during these times remains to be determined. (© 2020 Elsevier B.V. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|